(NASDAQ: IMDX) Insight Molecular Diagnostics's forecast annual revenue growth rate of 174.04% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 7.4%, and it is also forecast to beat the US market's average forecast revenue growth rate of 15.34%.
Insight Molecular Diagnostics's revenue in 2026 is $1,670,000.On average, 6 Wall Street analysts forecast IMDX's revenue for 2026 to be $71,666,182, with the lowest IMDX revenue forecast at $31,717,031, and the highest IMDX revenue forecast at $103,081,495. On average, 6 Wall Street analysts forecast IMDX's revenue for 2027 to be $257,867,358, with the lowest IMDX revenue forecast at $41,690,738, and the highest IMDX revenue forecast at $408,889,929.
In 2028, IMDX is forecast to generate $977,997,952 in revenue, with the lowest revenue forecast at $939,645,091 and the highest revenue forecast at $1,006,762,597.